17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics |
|
17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: {Abdulkerim}}
Overview
Although the precise incidence of 17βHSD-3 deficiency is unknown, a recent study from the Netherlands estimated the incidence around 1 in 147,000 newborns, with a calculated heterozygote frequency of 1 in 135.
Epidemiology and Demographics
- In the Netherlands, 17-beta-hydroxysteroid dehydrogenase deficiency is estimated to occur 1:147.000 newborns.
- It is more common in Gaza populations where it affects 1 in 200 to 300 people.
- The incidence of 17betaHSD3 deficiency is 0.65 times the incidence of AIS, which is thought to be the most frequent known cause of male pseudohermaphroditism without dysgenic gonads.[1]